Imfinzi Receives FDA Approval for Bladder Cancer Treatment

Key Takeaways

• FDA approved Imfinzi with gemcitabine and cisplatin neoadjuvantly, then Imfinzi alone after radical cystectomy, for adult MIBC on March 28, 2025.
• NIAGARA (NCT03732677) enrolled 1,063 cystectomy candidates without prior systemic bladder-cancer therapy.
• EFS hazard ratio was 0.68 (median EFS NR vs 46.1 months); OS hazard ratio was 0.75 at interim analysis.
• Earlier copy claiming a May 29, 2024 cisplatin-ineligible metastatic approval is incorrect and removed.

What indication did FDA grant for Imfinzi?

Per the FDA approval notice for durvalumab in MIBC, Imfinzi is indicated with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after radical cystectomy, for adults with muscle-invasive bladder cancer.

That perioperative label differs sharply from metastatic cisplatin-ineligible settings often discussed for other PD-1/L1 drugs. Teams should update forecasting models to resectable MIBC volumes, not metastatic second-line share alone.

What did NIAGARA show?

Efficacy came from NIAGARA, a randomized, open-label, multicenter Phase III trial. Patients were randomized 1:1 to neoadjuvant durvalumab plus chemotherapy then adjuvant durvalumab after surgery, or neoadjuvant chemotherapy then surgery alone.

• Primary endpoint: event-free survival by blinded independent central review.
• Additional endpoint: overall survival.
• EFS HR 0.68 (95% CI 0.56–0.82); two-sided p < 0.0001.
• OS HR 0.75 (95% CI 0.59–0.93); two-sided p = 0.0106.

Median EFS was not reached in the Imfinzi arm versus 46.1 months (95% CI 32.2–NR) with chemotherapy alone.

Where can clinicians verify the protocol?

The registration record is NCT03732677 on ClinicalTrials.gov. Label language for MIBC also appears in the FDA Imfinzi prescribing information (2025 label) under Indications and Usage 1.6.

NIAGARA results were presented at ESMO 2024 and published in the New England Journal of Medicine; FDA's numeric endpoints above are the regulatory reference for this rewrite.

How should competitors and BD teams respond?

Perioperative PD-L1 use raises the bar for neoadjuvant bladder programs still in Phase III. Comparators must show EFS/OS margins against chemo-surgery backbones that now include an approved immunotherapy option in the US.

Hospital pathways will need infusion capacity for neoadjuvant combination cycles and adjuvant Imfinzi after cystectomy. Contracting should separate MIBC perioperative from lung and biliary Imfinzi indications already on label.

What remains unproven after approval?

FDA documents efficacy in the NIAGARA population. Real-world adherence after cystectomy, outcomes in cisplatin-ineligible MIBC patients excluded from the chemo backbone, and long-term immune-related toxicity rates still need postmarketing evidence. Cross-trial claims versus other perioperative regimens are not established by this single approval.

Related NovaPharma coverage

• ESMO 2025 Preview: Astra and Daiichi vs Gilead
• May 2026 Regulatory Actions: Key Pharma Updates
• Vabysmo EU Approval for Retinal Vein Occlusion

Frequently Asked Questions

Primary Sources

1. FDA: durvalumab approved for muscle invasive bladder cancer
2. ClinicalTrials.gov: NIAGARA NCT03732677
3. FDA label: IMFINZI (durvalumab) prescribing information